Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902240 | 1.00 | HSD11B1 (0.52) | HSD11B1CHRM1NPC1RAB9ACCR5 | |
| SCHEMBL4092381 | 1.00 | HSD11B1 (0.52) | HSD11B1CHRM1NPC1RAB9ACCR5 | |
| SCHEMBL13902725 | 0.88 | HSD11B1 (0.67) | HSD11B1CHRM1CCR5 | |
| SCHEMBL13902645 | 0.85 | HSD11B1 (0.49) | HSD11B1CHRM1NPC1RAB9ACCR5 | |
| SCHEMBL4100469 | 0.82 | HSD11B1 (0.46) | HSD11B1NPC1RAB9ACCR5 | |
| SCHEMBL4100468 | 0.82 | HSD11B1 (0.46) | HSD11B1NPC1RAB9ACCR5 | |
| SCHEMBL13902451 | 0.80 | HSD11B1 (0.47) | HSD11B1CHRM1NPC1RAB9ACCR5 | |
| SCHEMBL13902458 | 0.80 | HSD11B1 (0.47) | HSD11B1CHRM1NPC1RAB9ACCR5 | |
| SCHEMBL13902460 | 0.75 | HSD11B1 (0.46) | HSD11B1NPC1RAB9A | |
| SCHEMBL4094854 | 0.75 | HSD11B1 (0.51) | HSD11B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CHRM1 4706/4885NPC1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.